Similar articles

• Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers.

  Gao H, Qu L, Li M, Guan X, Zhang S, Deng X, Wang J, Xing F. Gao H, et al. Int J Biol Macromol. 2025 Mar;297:139829. doi: 10.1016/j.ijbiomac.2025.139829. Epub 2025 Jan 13. Int J Biol Macromol. 2025. PMID: 39814310 Review.
• CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data.

  Anwar MY, Williams GR, Paluri RK. Anwar MY, et al. J Gastrointest Cancer. 2021 Mar;52(1):1-10. doi: 10.1007/s12029-020-00457-1. J Gastrointest Cancer. 2021. PMID: 32700185 Review.
• CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials.

  Drougkas K, Karampinos K, Karavolias I, Gomatou G, Koumprentziotis IA, Ploumaki I, Triantafyllou E, Kotteas E. Drougkas K, et al. J Gastrointest Cancer. 2024 Sep;55(3):990-1003. doi: 10.1007/s12029-024-01054-2. Epub 2024 May 2. J Gastrointest Cancer. 2024. PMID: 38695995 Review.
• Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.

  Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, Yang Q, Wang Y, Han W. Feng K, et al. Protein Cell. 2018 Oct;9(10):838-847. doi: 10.1007/s13238-017-0440-4. Epub 2017 Jul 14. Protein Cell. 2018. PMID: 28710747 Free PMC article. Clinical Trial.
• Novel immunotherapy strategies for hepatobiliary cancers.

  DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ. DeLeon TT, et al. Immunotherapy. 2018 Sep;10(12):1077-1091. doi: 10.2217/imt-2018-0024. Immunotherapy. 2018. PMID: 30185133 Review.